XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Reportable Segment Information
Reportable segment information was as follows:
 Three Months EndedNine Months Ended
September 30,September 30,
(DOLLARS IN MILLIONS)2022202120222021
Net sales:
Nourish$1,703 $1,662 $5,252 $4,638 
Health & Biosciences512 618 1,838 1,683 
Scent591 580 1,756 1,699 
Pharma Solutions257 211 750 605 
Consolidated$3,063 $3,071 $9,596 $8,625 
Segment Adjusted Operating EBITDA:
Nourish$287 $327 $981 $921 
Health & Biosciences137 151 513 469 
Scent119 130 328 375 
Pharma Solutions69 40 192 131 
Total612 648 2,014 1,896 
Depreciation & Amortization(293)(297)(897)(861)
Interest Expense(83)(74)(232)(216)
Other Income, net33 26 43 44 
Acquisition Related Costs (a)(1)— (2)— 
Restructuring and Other Charges 4 (6)(5)(34)
Gains on sales of fixed assets — 1 2 1 
Impairment of Goodwill (b)(2,250)— (2,250)— 
Impairment of Long-Lived Assets (c)— — (120)— 
Shareholder Activism Related Costs (d)— — (3)(7)
Business Divestiture Costs (e)(31)(16)(91)(21)
Employee Separation Costs (f)— (22)(4)(28)
Global Shared Services Implementation Costs (g)(1)— (1)— 
Frutarom Acquisition Related Costs (h)— — (1)— 
N&B Inventory Step-Up Costs — 14 — (363)
N&B Transaction Related Costs (i)— — — (91)
Integration Related Costs (j)(25)(24)(73)(80)
(Loss) Income Before Taxes$(2,035)$250 $(1,620)$240 
_______________________
(a)Represents costs related to the acquisition of Health Wright Products, primarily consulting and legal fees.
(b)Represents costs related to the impairment of goodwill in the Health & Biosciences reporting unit.
(c)Represents costs related to the impairment of intangible and fixed assets of an asset group that operates primarily in Russia.
(d)Represents shareholder activist related costs, primarily professional fees.
(e)Represents costs related to the Company's planned sales of businesses, primarily legal and professional fees.
(f)Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company.
(g)Represents costs related to the Company's efforts of restructuring the Global Shared Services Centers, primarily consulting fees.
(h)Represents transaction-related costs and expenses related to the acquisition of Frutarom.
(i)Represents transaction costs and expenses related to the transaction with N&B, primarily legal and professional fees.
(j)Represents costs related to integration activities since 2018, primarily for Frutarom and N&B. For 2022, represents costs primarily related to external consulting fees and internal integration costs, including salaries of individuals who are fully dedicated to integration efforts. For 2021, represents costs primarily related to performance stock awards and consulting fees for advisory services.
Net Sales by Destination of Product Delivery
Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2022202120222021
Europe, Africa and Middle East$1,030 $1,084 $3,258 $3,041 
Greater Asia701 696 2,200 1,990 
North America939 925 3,006 2,608 
Latin America393 366 1,132 986 
Consolidated$3,063 $3,071 $9,596 $8,625 
 Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2022202120222021
Net sales related to the U.S.$920 $860 $2,799 $2,390 
Net sales attributed to all foreign countries2,143 2,211 6,797 6,235